The purpose of the report is to illustrate the state of the market of Hospital Acquired Disease Testing, to present actual information about the volumes of production, exports, imports, consumption and the state of the market, the changes that took place in 2017, and also, to build a forecast for the growth of the industry in the medium term until 2026.
Browse here for full report with Toc: https://www.credenceresearch.com/report/hospital-acquired-disease-testing-market
Hospital acquired infections/diseases (HAIs) or nosocomial infections are defined to the infection acquired by patients during their stay in healthcare settings. Approximately 9.2 out of 100 patients in the U.S. acquire HAI. The most common types of HAIs include pneumonia, urinary tract infection, bloodstream infection, surgical site infection and others. HAIs are caused by pathogens among patients with compromised immune system, and negligence by hospital staff. The significant morbidity and mortality, the associated management costs and growing pressure from governing bodies have urged care-givers to devise accurate diagnosis of HAIs for efficient healthcare provision.
Some of the notable players in the hospital acquired disease testing market include Diatherix Corp, Roche, Cantel Medical Corporation, Qiagen, Cephid, bioMeriux and others.
Why was the report written?
This report is the result of an extensive survey drawn from Credence Research’s exclusive panel of leading global market industry executives; it provides data and analysis on buyer investment, acquisition, and developments within the global market research. It includes key topics such as global Hospital Acquired Disease Testing buyer expenditure and procurement behaviors and strategies and recognizes the threats and possibilities within the industry, economic outlook trends, and business confidence within global industry executives. Most secondary research reports are based on general industry drivers and do not understand the industry executives’ attitude and changing behaviors, creating a gap in presenting the business outlook of the industry; in an effort to bridge this gap, Credence Research created this primary research-based report by gathering the opinions of multiple stakeholders in the value chain of the global industry.
What is the current market landscape and what is changing?
Executives from the global industry anticipate an increase in levels of consolidation, with 55% of respondents projecting an increase in merger and acquisition (M&A) activities in 2017.
The report on the market of Hospital Acquired Disease Testing contains:
Analysis and forecast of Hospital Acquired Disease Testing market dynamics;
Analysis of domestic production, market shares of the main market players;
Analysis of exports and imports;
Analysis of factors, leading the development of the Hospital Acquired Disease Testing market;
Assessment and forecast of Hospital Acquired Disease Testing market development;
Financial and business profiles of the leading companies in the Hospital Acquired Disease Testing industry.
Also you can request us for sample in PDF with depth details and graph: https://www.credenceresearch.com/sample-request/57814
– Up to date working Hospital Acquired Disease Testing data by major regions in the world, the forecast of planned capacity additions by 2026
– The annual breakdown of capital expenditure spending on proposed Hospital Acquired Disease Testing for the period 2018 to 2026
– Planned Hospital Acquired Disease Testing additions and capital expenditure spending by key countries and companies across the world
– Planned capital expenditure spending on new Hospital Acquired Disease Testing projects by region, key countries, and companies
– Details of major planned Hospital Acquired Disease Testing projects in the world up to 2026
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Credence Research Inc.
105 N 1st ST #429
Toll Free (US/CANADA): +1-800-361-8290